Why ISIS Pharmaceuticals' Shares Dipped

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biotechnology company ISIS Pharmaceuticals (Nasdaq: ISIS  ) dropped as much as 11% earlier in the trading session after reporting disappointing third-quarter earnings results.

So what: For the quarter, ISIS reported a higher loss per share relative to last year of $0.37 and revenue of $11.6 million. Although earnings reports aren't closely monitored by investors of clinical-stage companies, shareholders seem peeved that EPS was $0.10 worse than expected, and revenue was about half of Wall Street's forecast.

Now what: I don't often say this, but consider today's earnings report a short-term event -- perhaps even a non-event. All eyes should be on ISIS' homozygous familial hypercholesterolemia drug, Kynamro, which is being developed in collaboration with Sanofi (NYSE: SNY  )  and received a statistically favorable, but still worrisome, 9-6 nod to recommend the drug by the Food and Drug Administration panel. At the moment, Aegerion Pharmaceuticals' (Nasdaq: AEGR  ) lomitapide has a more clear and severe side-effect free path to approval than Kynamro, and investors will want to keep a close eye on both drugs in the coming months as we approach their FDA judgment day.

Craving more input? Start by adding ISIS Pharmaceuticals to your free and personalized Watchlist so you can keep up on the latest news with the company.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2098503, ~/Articles/ArticleHandler.aspx, 4/20/2014 6:36:16 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement